company background image
TMBR

Timber Pharmaceuticals NYSEAM:TMBR Stock Report

Last Price

US$0.13

Market Cap

US$16.6m

7D

20.9%

1Y

-87.6%

Updated

16 Aug, 2022

Data

Company Financials +
TMBR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

TMBR Stock Overview

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases.

Timber Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Timber Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.13
52 Week HighUS$1.12
52 Week LowUS$0.09
Beta-0.17
1 Month Change-56.76%
3 Month Change-48.82%
1 Year Change-87.58%
3 Year Changen/a
5 Year Changen/a
Change since IPO-96.95%

Recent News & Updates

Shareholder Returns

TMBRUS PharmaceuticalsUS Market
7D20.9%0.3%4.5%
1Y-87.6%-0.9%-8.9%

Return vs Industry: TMBR underperformed the US Pharmaceuticals industry which returned 0.3% over the past year.

Return vs Market: TMBR underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is TMBR's price volatile compared to industry and market?
TMBR volatility
TMBR Average Weekly Movement20.0%
Pharmaceuticals Industry Average Movement12.1%
Market Average Movement7.6%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: TMBR is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: TMBR's weekly volatility has increased from 14% to 20% over the past year.

About the Company

FoundedEmployeesCEOWebsite
20195John Koconishttps://www.timberpharma.com

Timber Pharmaceuticals LLC, a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company’s lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-002, a proprietary topical formulation of rapamycin, which is in Phase 2b clinical trial for the treatment of facial angiofibroma in tuberous sclerosis complex, a multisystem genetic disorder resulting in the growth of hamartomas in multiple organs. It is also involved in the development of TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases.

Timber Pharmaceuticals, Inc. Fundamentals Summary

How do Timber Pharmaceuticals's earnings and revenue compare to its market cap?
TMBR fundamental statistics
Market CapUS$16.61m
Earnings (TTM)-US$18.43m
Revenue (TTM)US$540.16k

30.8x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TMBR income statement (TTM)
RevenueUS$540.16k
Cost of RevenueUS$12.91m
Gross Profit-US$12.37m
Other ExpensesUS$6.06m
Earnings-US$18.43m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.14
Gross Margin-2,290.13%
Net Profit Margin-3,411.22%
Debt/Equity Ratio159.4%

How did TMBR perform over the long term?

See historical performance and comparison